Evaluation of Investigational (Frequent Replacement) FRP Lens for Daily Wear
NCT ID: NCT02362724
Last Updated: 2020-10-14
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
89 participants
INTERVENTIONAL
2015-02-28
2015-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The study results were not used for design validation of investigational contact lens,
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Evaluation of Monthly Replacement Lenses in Habitual Soft Contact Lens Wearers Who Report Frequent Digital Devise Use
NCT05166902
Evaluation of Silicone Hydrogel Daily Wear Contact Lenses for Up to One (1) Month of Daily Wear
NCT03722784
A Contralateral Dispensing Clinical Trial of Study Test Sapphire Lens Against Enfilcon A Silicone Hydrogel Lens
NCT02518490
A Bilateral Dispensing Clinical Trial of Sapphire Lens Against Senofilcon A Lens Over 2 Weeks
NCT02345811
Daily Disposable Silicone Hydrogel Contact Lens, Stenfilcon A, Clinical Study
NCT02637804
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The study results were not used for design validation of investigational contact lens,
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Sapphire
Subjects randomized to the experimental contact lens over the study duration
Sapphire
silicone hydrogel contact lens
Pearl
Subjects randomized to the active comparator contact lens over the study duration
Pearl
silicone hydrogel contact lens
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Sapphire
silicone hydrogel contact lens
Pearl
silicone hydrogel contact lens
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
1. Be at least 18 years of age as of the date of evaluation for the study.
2. Have:
1. Read the Informed Consent
2. been given an explanation of the Informed Consent
3. indicated understanding of the Informed Consent
4. signed the Informed Consent document.
3. Be willing and able to adhere to the instructions set forth in this protocol and able to keep all specified appointments.
4. Be an adapted, current full-time silicone hydrogel or soft contact lens wearer. An adapted full-time wearer is defined as wearing contact lenses at least 5 days per week for at least 8 hours per day for at least one month prior to participation in the study.
5. Possess or obtain prior to dispensing, wearable and visually functional (20/40 or better) eyeglasses.
6. Be in good general health, based on his/her knowledge.
7. Require spectacle lens powers between -0.50 and -8.00 diopters sphere with no more than 1.50 diopter of refractive astigmatism and be willing to wear contact lenses in both eyes.
8. Have manifest refraction Snellen visual acuities (VA) equal to or better than 20/25 in each eye.
9. To be eligible for lens dispensing, the subject must achieve 20/30 VA or better in each eye with the study lens and the investigator must judge the fit as acceptable or optimal.
Exclusion Criteria
1. Wearing lenses in a monovision modality and is unwilling to be fit with distance lenses in both eyes for the duration of the study. NOTE: Subjects may not wear lenses in a monovision modality at any time during the study as it will interfere with the visual acuity analysis.
2. Poor personal hygiene.
3. Any active participation in another clinical trial during this trial or within 30 days prior to this study.
4. To the best of the subject's knowledge, she is currently pregnant, is lactating or is planning a pregnancy within the next 3 months.
5. A member, relative or household member of the investigator or of the investigational office staff.
6. Has a known sensitivity to the ingredients used in the MPS approved for use in the study and is unable or unwilling to use the alternate care system.
7. Previous refractive surgery; or current or previous orthokeratology treatment.
8. Is aphakic or psuedophakic.
9. Ocular or systemic disease such as, but not limited to: anterior uveitis or iritis (past or present), glaucoma, Sjögren's syndrome, lupus erythematosus, scleroderma, keratoconus or uncontrolled diabetes.
10. The need for topical ocular medications or any systemic medication which might interfere with contact lens wear or require the lenses to be removed during the day.
11. The presence of clinically significant (grade 2, 3 or 4) anterior segment abnormalities; or the presence of any inflammations such as iritis; or any infection of the eye, lids, or associated structures.
12. A known history of corneal hypoesthesia (reduced corneal sensitivity), corneal ulcer, corneal infiltrates, iritis, bacterial or fungal infections.
13. A history of papillary conjunctivitis that has interfered with contact lens wear.
14. Slit lamp findings that would contraindicate contact lens wear, including but not limited to:
* Pathological dry eye or associated dry eye symptoms with decreased tear levels and punctuate staining \> Grade 2
* Pterygium
* Corneal scars within the visual axis
* Neovascularization or ghost vessels \> 1.0 mm in from the limbus
* Giant papillary conjunctivitis (GPC) of \> Grade 2
* Anterior uveitis or iritis
* Seborrheic eczema, seborrheic conjunctivitis or blepharitis
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
CooperVision, Inc.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Steven L Saltzman, MD, FACOG
Role: STUDY_CHAIR
Sterling IRB
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Eric M White OD, Inc.
San Diego, California, United States
Office of Mark E Nakano, O.D.
Torrance, California, United States
Advanced Family Eye Care
Denver, North Carolina, United States
Quinn Foster & Associates
Athens, Ohio, United States
Primary Eyecare Group, P.C.
Brentwood, Tennessee, United States
Premier Vision Services, LLC
Amarillo, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FC131202
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.